A phase II/III, observer-blinded, multi-country, multi-centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years or older compared to Fluarix.

Trial Profile

A phase II/III, observer-blinded, multi-country, multi-centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years or older compared to Fluarix.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs GSK 576389A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Oct 2008 Phase changed from II/III to II as reported by Clinicaltrials.gov.
    • 12 Jan 2007 Status change
    • 08 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top